MINI FUTURE OPTIONSSCHEIN - VERTEX PHARMACEUTICALS | Market Closed - Börse Stuttgart 15:47:34 2024-05-31 EDT | ||
| 16.45 EUR | -7.74% |
|
| 1 month | -26.86% | ||
| 3 months | -16.03% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-05-31 | 16.45 | -7.74% |
| 24-05-30 | 17.83 | -0.17% |
| 24-05-29 | 17.86 | +11.56% |
| 24-05-28 | 16.01 | +0.06% |
| 24-05-27 | 16 | -2.56% |
Delayed Quote Börse Stuttgart
Last update May 31, 2024 at 03:47 pm
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | J.P. Morgan |
| WKN | JB9R7X |
| ISIN | DE000JB9R7X2 |
| Date issued | 2023-12-27 |
| Strike | 634.2 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 21.15 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 22.8 € |
|---|---|
| Lowest since issue | 15.87 € |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
455.3
USD
Average target price
463.5
USD
Spread / Average Target
+1.80%
- Stock Market
- Certificates
- Certificat
